

PRODUCT INFORMATION

BCMA/CD269 Polyclonal Antibody

Item No. 43761

Overview and Properties

Contents:	This vial contains 20 or 100 µl of protein A-affinity purified polyclonal antibody.
Synonyms:	B cell Maturation Antigen, B cell Maturation Protein, BCMP, TNF Receptor Superfamily Member 17, TNFRSF17
Immunogen:	Recombinant human BCMA
Cross Reactivity:	(+) BCMA
Species Reactivity:	(+) Human
Form:	Liquid
Storage:	-80°C (as supplied)
Stability:	≥1 year
Storage Buffer:	0.2 µm filtered solution in PBS
Host:	Rabbit
Isotype:	IgG
Application:	ELISA; the recommended starting dilution is 1:5,000-1:10,000. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

Description

B cell maturation antigen (BCMA), also known as CD269, is a member of the TNF receptor superfamily.¹ It is composed of an extracellular domain, a transmembrane region, and a cytoplasmic domain.^{1,2} BCMA is found in the cell membrane of late memory B cells and recognizes TNF superfamily member 13B (TNFSF13B), also known as B cell activating factor (BAFF), and a proliferation-inducing ligand (APRIL), which both promote B cell survival and differentiation into short- or long-lived plasma cells, antibody production, and immunoglobulin class switching.^{1,3} The extracellular domain of BCMA can be cleaved by γ-secretase to release soluble BCMA (sBCMA), which can bind APRIL and prevent APRIL-induced signaling in B cells, reducing B cell survival.² Increased sBCMA levels are associated with lower progression-free- and overall survival in patients with multiple myeloma.⁴ Cayman's BCMA/CD269 Polyclonal Antibody can be used for ELISA.

References

1. Cho, S.-F., Anderson, K.C., and Tai, Y.-T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. *Front. Immunol.* **9**, 1821 (2018).
2. Laurent, S.A., Hoffmann, F.S., Kuhn, P.-H., et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. *Nat. Commun.* **6**, 7333 (2015).
3. Stohl, W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. *Endocr. Metab. Immune Disord. Drug Targets* **6**(4), 351-358 (2006).
4. Ghermezi, M., Li, M., Vardanyan, S., et al. Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients. *Haematologica* **102**(4), 785-795 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/15/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM